Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 2/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.43 |
| ▸ | GABRP | O00591 | 1/20 | 0.43 |
| ▸ | GABRD | O14764 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.43 |
| ▸ | GABRE | P78334 | 1/20 | 0.43 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.43 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.43 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.43 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30814775 | 0.89 | GABRP (0.39) | GABRG2GABRB3GABRA5GABRA3GABRP | |
| SCHEMBL23663360 | 0.84 | ABCB1 (0.51) | FFAR1PDGFRBPDGFRAMAOBAPP | |
| SCHEMBL20522582 | 0.83 | GABRG2 (0.43) | GABRG2GABRB3GABRA5GABRA3GABRP | |
| SCHEMBL15968679 | 0.80 | FOLH1 (0.50) | GABRG2GABRB3GABRA5GABRA3GABRP | |
| SCHEMBL22712757 | 0.80 | GABRP (0.42) | GABRG2GABRB3GABRA5GABRA3GABRP | |
| SCHEMBL22712746 | 0.79 | MAOB (0.47) | GABRG2GABRB3GABRA5GABRA3GABRP | |
| SCHEMBL17541475 | 0.79 | TUBB4A (0.34) | GABRG2GABRB3GABRA5GABRA3GABRP | |
| SCHEMBL29755761 | 0.78 | GABRA5 (0.48) | GABRG2GABRB3GABRA5GABRA3GABRP | |
| SCHEMBL23301902 | 0.78 | GABRA5 (0.48) | GABRG2GABRB3GABRA5GABRA3GABRP | |
| SCHEMBL15968225 | 0.77 | MEN1 (0.43) | GABRG2GABRB3GABRA5GABRA3GABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968231-B2 | Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders | SCOHIA PHARMA, INC. (JP) | 2021-04-06 | — | — | US | disclosed |
| US-20200377509-A1 | SUBSTITUTED CYCLYL-ACETIC ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-12-03 | — | — | US | disclosed |
| EP-3601260-A1 | SUBSTITUTED CYCLYL-ACETIC ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | Takeda Pharmaceutical Company Limited (JP) | 2020-02-05 | — | — | EP | disclosed |
| CN-110678458-A | Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders | 武田药品工业株式会社 | 2020-01-10 | — | — | CN | disclosed |
| WO-2018182050-A1 | SUBSTITUTED CYCLYL-ACETIC ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-04 | — | — | WO | disclosed |
| US-8536338-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-09-17 | — | — | US | disclosed |
| EP-2545050-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2013-01-16 | — | — | EP | disclosed |
| US-8293909-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-23 | — | — | US | disclosed |
| US-20120232099-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-13 | — | — | US | disclosed |
| US-8198449-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-06-12 | — | — | US | disclosed |
| WO-2011112186-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-15 | — | — | WO | disclosed |
| EP-2331502-A2 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2011-06-15 | — | — | EP | disclosed |
| US-20100184800-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-22 | — | — | US | disclosed |
| WO-2010030538-A2 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20100063068-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968231-B2 | Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders | GLP1R, GPR119, GPR65 | GABRG2 1274/4885GABRB3 1545/4885GABRA5 615/4885 |
| US-20100063068-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | GABRG2 2617/4885GABRB3 2466/4885GABRA5 3887/4885 |
| US-20100184800-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | GABRG2 2617/4885GABRB3 2466/4885GABRA5 3887/4885 |
| US-20120232099-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | GABRG2 2617/4885GABRB3 2466/4885GABRA5 3887/4885 |
| US-20200377509-A1 | SUBSTITUTED CYCLYL-ACETIC ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC DISORDERS | GLP1R, GPR119, GPR65 | GABRG2 1274/4885GABRB3 1545/4885GABRA5 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.